Exciting progress is being made in the treatment of androgenetic alopecia as Rubedo advances its compound RLS-1496. Backed by the VitaDAO community, this upcoming research represents the inaugural clinical trial of a GPX4 modulator designed specifically to address hair loss. Ex vivo studies measuring hair elongation against a vehicle control have already yielded promising results, with the maximum dosage demonstrating a growth trend that exceeded that of finasteride. The clinical trial is scheduled to commence in October 2026, and the resulting data is anticipated to be available during the first half of 2027. For further details, please visit https://www.businesswire.com/news/home/20260916811892/en/Rubedo-Life-Sciences-Announces-Clinical-Study-to-Treat-Hair-Loss-with-GPX4-Modulator-RLS-1496-First-Human-Ex-Vivo-Evidence-Demonstrates-Robust-Hair-Follicle-Growth